Drug Profile
PRX 07034
Alternative Names: PRX-07034Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Class Nootropics; Obesity therapies
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity in USA (PO)